Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to CD28 signaling domains. And the vector product was designed for the treatment of glioma.
|
CAR Construction :
Fig.1 Calibration curve of the binding of RAbDMvIII and RAbvIII recombinant antibodies to coated EGFRvIII in the ELISA. The concentration range for RAbDMvIII and RAbvIII was 20 to 0.02 ug/ml (x axis) and the absorbance was read at 450 nm (Y axis). The assay was analyzed twice. Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13. |
|
CAR Construction :
Fig.2 NIH3T3 and HC2 cells were mixed in a 1:1 ratio prior to staining with RAbDMvIII revealing distinct identification of an EGFRvIII cell population. The dot blot (left panel) represents human-IgG1 isotype control. Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13. |
|
CAR Construction :
Fig.3 Affinity determination of RAbDMvIII by Saturation ELISA. Saturation ELISA shows the Scatchard plot of the binding of RAbDMvIII to EGFRvIII. Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13. |
|
CAR Construction :
Fig.4 Specificity of RAbDMvII1 by Flow cytometry. Freshly dissociated human GBM tumor stained with RAbDMvIII shows Gupta, P., Han, S. Y., Holgado-Madruga, M., Mitra, S. S., Li, G., Nitta, R. T., & Wong, A. J. (2010). Development of an EGFRvIII specific recombinant antibody. BMC biotechnology, 10(1), 1-13. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-EGFRvIII scFv h(CD28) CART, pCDCAR1 (CAR-T-1-M315-2). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
